1.Comparison of zhibituo and lovastatin in the treatment of hyperlipidemia
Qiaoyun CHEN ; Shuiyi WEI ; Xiaoh LU
Journal of Medical Postgraduates 2003;0(03):-
Objective:To compare the efficacy, safety and economics of zhibituo and lovastatin in the treatment of hyperlipidemia. Methods:Searching medical references were done, The qualified results of clinical trials were Meta-analysed for evaluating the efficacy of zhibituo comparing with lovastatin. The characters of zhibituo and lovastatin were also compared through scoring by senior physicians. Results:The results of Meta-analysis showed that zhibituo had stronger effects on lowering TG and elevating HDL.It had less severe ADR for old people and cost less than lovastatin. The results of physicians-scoring records showed no significant difference between these two drugs. Conclusion:Zhibituo and lovastatin both are potential lipid-lowering agents. zhibituo is safer and more cost-effective for old people with mild to moderate elevated serum LDL level.
2.Consideration to the Promotion of Education and Research of Social Pharmacy
Wengong CHU ; Shuiyi WEI ; Wenhua GU
China Pharmacy 2001;0(10):-
OBJECTIVE:To promote the education and research of social pharmacy in China METHODS:This article introduces the definition of social pharmacy,the history and current situation in foreign countries,and to analyse the history and development of pharmacy administration in China RESULTS & CONCLUSION:Some preliminary suggestions about the promotion of education and research of social pharmacy in China are put forward
3.Study on the Drug Utilization for Lower Respiratory Tract Diseases
Shengxin CHEN ; Jingxia ZHAO ; Zhigao HE ; Shuiyi WEI ; Lixin SHU
Chinese Journal of Pharmacoepidemiology 2001;10(1):19-21
To study the status and patterns of the drug utilization in the diseases of lower respiratory tract, the drug utilization for 290 inpatients with respiratory tract diseases in a Shanghai hospital druing 1993-1997 was analyzed by using Acute Physiology, Age, Chronic Health Evaluation(APACHE) and index of defined daily dose numbers(DDDs). The relativity between APACHE and DDDs was studied. It was found that most common drugs was anti-infection agents and expectorants, accounting for 39.06% and 38.38 %, respectively. The quantitative relationship between drug consumption and disease severity was not observed. It is concluded that the status of the drug utilization can't be demonstrated by analyzing the frequency of drug use by using DDDs.
4.Clinical correlation between incipient C-reactive protein and kidney injury of anti-neutrophil cytoplasmic antibody associated vasculitis
Miaomiao ZHANG ; Pengcheng XU ; Shuiyi HU ; Li WEI ; Junya JIA ; Jianqing JIANG ; Tiekun YAN ; Shan LIN
Chinese Journal of Nephrology 2018;34(3):167-172
Objective To investigate the relationship between the incipient serum C-reactive protein (CRP) and clinicopathologic features in anti-neutrophil cytoplasmic antibody associated vasculitis (AAV).Methods Data of 138 consecutive AAV patients were collected.According to their serum CRP levels,patients were divided into group 1 with normal CRP,group 2 with slightly increased CRP and group 3 with severely increased CRP.Clinical features of AAV and histopathologic features of the kidney injury were compared among groups.Results CRP levels increased in 77.53% AAV patients on admission.Patients in the group of severely increased CRP had the highest levels of BVAS,serum C3,serum ANCA titer,leukocyte counts and the lowest levels of hemoglobin and albumin among the 3 groups (all P < 0.05).The mortality during the stage of therapy was highest in patients with severely increased CRP (P < 0.05).The focal kidney damage was more obvious in patients with severely increased CRP.There was no significant difference in renal prognosis among patients with different CRP levels.Conclusion The levels of incipient serum C-reactive protein of AAV vary in different patients and are positively correlated with patients' inflammation status as well as the disease activity,but are not correlated with the severity of kidney injury.